Last reviewed · How we verify
Factor XIIa antagonist monoclonal antibody
At a glance
| Generic name | Factor XIIa antagonist monoclonal antibody |
|---|---|
| Also known as | CSL312 |
| Sponsor | CSL Behring |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis (PHASE2)
- A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) (PHASE2)
- A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects (PHASE1)
- A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults (PHASE1)
- Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Factor XIIa antagonist monoclonal antibody CI brief — competitive landscape report
- Factor XIIa antagonist monoclonal antibody updates RSS · CI watch RSS
- CSL Behring portfolio CI